Also trades as: 0JBU.L (LSE) · $vol 0M
NTLA NASDAQ
Intellia Therapeutics, Inc.
1W: +3.7%
1M: +7.5%
3M: +13.7%
YTD: +33.3%
1Y: -52.0%
3Y: -53.9%
5Y: -90.7%
$12.28
+1.02 (+9.06%)
Weekly Expected Move ±8.1%
$9
$10
$11
$12
$13
Credit Risk of going bust: higher than 67% of companies Debt: 4.1% of company value Bonds: none of note held by US funds details ▾
Of US companies ranked in the middle of the pack, about 1 in 580 filed for bankruptcy within a year (2020-2025).
If the stock fell to about $0.10 (down 99.2%), Intellia Therapeutics, Inc. would be worth roughly what it owes.
Total debt $73.4M against a stock market value of $1.72B.
Distance to default 3.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.7M (short-term plus half of long-term), stock volatility 96.6%; Altman Z'' -4.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
If the stock fell to about $0.10 (down 99.2%), Intellia Therapeutics, Inc. would be worth roughly what it owes.
Total debt $73.4M against a stock market value of $1.72B.
Distance to default 3.66 (Merton model): prices to 2026-10-27, balance sheet 2026-06-30, debt counted $36.7M (short-term plus half of long-term), stock volatility 96.6%; Altman Z'' -4.42. A ranking and a back-test, not a forecast.
US fund filings (SEC N-PORT) show under $25M of this company's bonds, so there is no bond page. Its debt may be bank loans or privately placed. How these are computed.
Overview
News
Chart
Smart Money
Financials
Income Statement
Cash Flow
Balance Sheet
Earnings
Dividends
Analysis
Technicals
Weather
Peers
ESG
Institutions
ETF Exposure
Dark Pool
Short Interest
Supply Chain
Supply Chain Overview
10 relationships10
As Filer
counterparties named
0
As Counterparty
mentioned by others
3
Rel. Types
2021-06-17
Earliest Filing
2026-03-02
Latest Filing
partner: 8
acquirer: 1
target: 1
Counterparties (Filed by NTLA)
10 relationshipsCompanies named in NTLA's SEC 8-K filings as business counterparties.
| Counterparty | Ticker | Relationship | Summary | Filing Date | SEC |
|---|---|---|---|---|---|
| Jefferies LLC | JEF | partner | Sales agent for the at-the-market offering program | 2026-03-02 | View |
| Alexandria Real Estate Equities, Inc. | ARE | partner | Landlord for office and laboratory space lease agreements | 2025-02-21 | View |
| ARE-Tech Square, LLC | — | partner | Affiliate of Alexandria Real Estate Equities, Inc. acting as landlord | 2025-02-21 | View |
| ARE-Winter Street Property, LLC | — | partner | Affiliate of Alexandria Real Estate Equities, Inc. acting as landlord | 2025-02-21 | View |
| Jefferies LLC | JEF | partner | Sales agent for the at-the-market offering program | 2024-02-23 | View |
| Jefferies LLC | JEF | partner | Sales agent for the Company's at-the-market offering program. | 2022-03-04 | View |
| RW Acquisition Corp. | — | acquirer | Merger Sub entity merging with Rewrite Therapeutics | 2022-02-03 | View |
| Rewrite Therapeutics, Inc. | — | target | Target company acquired in the merger agreement | 2022-02-03 | View |
| Novartis Institutes for Biomedical Research, Inc. | NVSEF | partner | Amendment to License and Collaborative Research Agreement regarding CAR-T Therapeutic Targets | 2021-06-17 | View |
| Caribou Biosciences, Inc. | CRBU | partner | Leaseback Agreement to settle arbitration and license CRISPR/Cas9 IP for CB-010 product candidate | 2021-06-17 | View |
Recent 8-K Filings (20)
| Filing Date | Description | Type | SEC |
|---|---|---|---|
| 2026-09-08 | Regulation FD; Other Events; Exhibits | View | |
| 2026-09-04 | Material Agreement; Financial Obligation; Regulation FD; Exhibits | Agreement | View |
| 2026-08-06 | Earnings Release; Exhibits | View | |
| 2026-06-15 | Regulation FD; Other Events; Exhibits | View | |
| 2026-06-10 | Shareholder Vote | View | |
| 2026-05-11 | Earnings Release; Exhibits | View | |
| 2026-04-30 | Material Agreement; Earnings Release; Exhibits | Agreement | View |
| 2026-04-27 | Regulation FD; Other Events; Exhibits | View | |
| 2026-04-10 | Bylaws Amendment; Exhibits | View | |
| 2026-03-02 | Entry into Material Definitive Agreement; Regulation FD Disclosure; Other Events; Financial Statemen | Agreement | View |
| 2026-02-26 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2026-01-27 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2026-01-09 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-10 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-11-06 | Results of Operations and Financial Condition; Financial Statements and Exhibits | View | |
| 2025-10-29 | Other Events | View | |
| 2025-10-27 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-09-25 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View | |
| 2025-08-07 | Results of Operations and Financial Condition; Departure/Election of Directors; Appointment of Offic | View | |
| 2025-06-16 | Regulation FD Disclosure; Other Events; Financial Statements and Exhibits | View |
Data extracted from SEC EDGAR 8-K filings using NLP. Relationships are as disclosed in filing text.
Covers 2021–2026. View on SEC EDGAR